难治性抑郁症患者血清神经生长因子水平与电休克治疗缓解的关系

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (1184 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the correlation between serum nerve growth factor (NGF) level and the effect of electroconvulsive therapy (ECT) in patients with treatment-resistant depression (TRD). Methods Sixty patients with TRD (TRD group) in the 987th Hospital of PLA Joint Logistics Support Force from February 2020 to December 2021 were enrolled, and 60 healthy volunteers in the same period were selected as control group. All patients with TRD received ECT treatment with ketamine alone for 8 times. Serum NGF level was detected by enzyme-linked immunosorbent assay (ELISA). Hamilton Depression Rating Scale (HAMD-17) and Brief Psychiatric Rating Scale (BPRS) were used to evaluate the severity of illness. Results The baseline serum NGF level in TRD group was significantly lower than that in the control group (P＜0.001). According to the receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) of baseline serum NGF level in diagnosing TRD was 0.953. The remission rate of antidepressant was 76.7% (46/60). With ECT treatment, serum NGF level increased (P＜0.001). The serum NGF level of TRD patients in the remission group was always higher than that in the non-remission group (P＜0.001). The increase trend of serum NGF level in TRD patients in the remission group was significantly higher than that in non-remission group (P=0.001). The changes of serum NGF level were negatively correlated with the changes of HAMD-17 score and BPRS score P＜0.05). The AUC of baseline serum NGF level in predicting non-remission of ECT treatment in TRD patients was 0.750. Baseline serum NGF level＞7.97 pg/ml was still an independent risk factor affecting the remission outcome of ECT in TRD patients (P=0.015). Conclusions During ECT treatment, the serum NGF level of TRD patients gradually increases with the improvement of the disease, and the baseline serum NGF level can be used as a biomarker to predict the remission of TRD patients after ECT treatment.

Key words： treatment-resistant depression nerve growth factor electroconvulsive therapy neural plasticity

Received: 17 April 2023

ZTFLH:

R749.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Ting
	SONG Zhao
	HUA Zhen
	LIU Guangxiong
	LI Yaping
	WANG Jin
	andWU Xingqu

Cite this article:

JIA Ting,SONG Zhao,HUA Zhen等. Relationship between serum nerve growth factor level and effect of electroconvulsive therapy in patients with treatment-resistant depression[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(10): 884-888.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I10/884

[1]	王冬, 汤艳清. 重度抑郁症与肠道菌群关系的研究进展[J]. 中国医科大学学报,2022,51(3):259-262.
[2]	王惠芹,王真真,林美妤,等. 抑郁症发病与神经营养因子异常研究进展[J]. 中国药理学通报,2020,36(10):1333-1337.
[3]	徐国安, 李广学, 高树贵. 无抽搐电休克治疗与脑源性神经营养因子相关性研究进展[J]. 临床荟萃, 2018, 33(4): 365-368.
[4]	李一兰, 李淑云, 童梓顺,等. 抑郁症治疗前后神经及认知执行功能的变化和相关性研究[J]. 中国医药科学, 2021, 11(18): 18-22.
[5]	乔娟, 阎锐, 陈瑜,等. 焦虑性抑郁症患者脑灰质体积变化及其与临床特征的相关性[J]. 中华行为医学与脑科学杂志, 2022, 31(1): 25-30.
[6]	胡少华. 难治性抑郁症及其诊断治疗[J]. 四川精神卫生, 2022, 35(1): 1-5.
[7]	宋美, 王岚, 王冉,等. 酒精使用障碍家族史对男性不良饮酒行为及酒精使用障碍患病的影响[J]. 神经疾病与精神卫生, 2022, 22(8): 547-552.
[8]	费诗琪, 董丽平, 童萍,等. 抑郁症患者治疗前血清补体C1q水平与电休克治疗疗效的关系[J]. 临床精神医学杂志, 2022, 32(6): 496-471.
[9]	Zheng W, Cen Q, Nie S, et al. Serum BDNF levels and the antidepressant effects of electroconvulsive therapy with ketamine anaesthesia: a preliminary study[J]. PeerJ, 2021,9:e10699.
[10]	孔盖, 沈梦婷, 张选红,等. 不同靶点和定位方法的经颅磁刺激治疗抑郁症的疗效比较[J]. 中华精神科杂志, 2022, 55(1): 24-29.
[11]	王惠芹, 王真真, 林美妤, 等. 神经营养因子异常与抑郁症发病机制研究进展[J]. 中国药理学与毒理学杂志, 2020, 36(10): 1333-1337.
[12]	徐淑娴, 荣晗, 谢新晖,等. 电休克治疗抑郁症的神经发生机制研究进展[J]. 神经疾病与精神卫生, 2022, 22(3): 1009-6574.
[13]	杨文海,宁显忠,赵德福,等. 抑郁症患者血清中脑源性神经营养因子和皮质醇的表达[J]. 中国老年学杂志,2018,38(21):5252-5253.
[14]	Rocco ML, Soligo M, Manni L, et al. Nerve growth factor: early studies and recent clinical trials[J]. Curr Neuropharmacol, 2018,16(10):1455-1465.
[15]	Wiener C D, de Mello Ferreira S, Pedrotti Moreira F, et al. Serum levels of nerve growth factor (NGF) in patients with major depression disorder and suicide risk[J]. J Affect Disord, 2015,184:245-248.
[16]	Wang H, Yang Y, Pei G, et al.Neurotrophic basis to the pathogenesis of depression and phytotherapy[J]. Front Pharmacol, 2023,14: 1182666.